Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Momentum forward
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(50)
•••
Comment by CarbonWarrioron Nov 24, 2022 4:11pm
151 Views
Post# 35126216

RE:RE:RE:RE:RE:RE:RE:Momentum forward

RE:RE:RE:RE:RE:RE:RE:Momentum forward
Plenty of people lost plenty of Money Elon twitter fiasco =44Billions
Zuckerburg = -85 Billion Meta madness
Crypto implosion...


But but but there is still plenty of people that have money for a speculative bet.

ONCY is nice to look at.
Place your bet here and ride it up to 6$.

This is the best play in around for a nice return.

You got two big pharma waiting to make an offer
Awesome data ---
Complete share price capitulation (trading at 3X cash value.. lol...) 
Potential cancer cure... wow
Cheap, undervalued and prime for a major repricing ...

Why so sad? This baby is a BAD. This baby goes to 6$ easy and test 10$ before deal day.

Buy a truck load, sell 1/3 of it at 6$ let the rest rise to the moooooon, and exit as you please higher. Easy play. Easy money. Momentum play.






<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities